Table 3. Associations between the GPER mRNA expressions in the METABRIC cohort with clinicopathological variables.
| GPER probe 1 | GPER probe 2 | ||||||
|---|---|---|---|---|---|---|---|
| low | high | P value | low | high | P value | ||
| PAM 50 subtype | Basal | 208 (10.5%) | 123 (6.2%) | <0.001 | 124 (6.3%) | 207 (10.5%) | <0.001 |
| HER2 | 183 (9.3%) | 56 (2.8%) | 100 (5.1%) | 139 (7.0%) | |||
| Luminal A | 241 (12.2%) | 472 (23.9%) | 78 (4.0%) | 637 (32.3%) | |||
| Luminal B | 220 (11.1%) | 270 (13.7%) | 117 (5.9%) | 372 (18.9%) | |||
| Normal | 49 (2.5%) | 150 (7.6%) | 15 (0.8%) | 184 (9.3%) | |||
| P53 mutation status | Mutated | 65 (8.0%) | 34 (4.2%) | <0.001 | 49 (6.0%) | 50 (6.1%) | <0.001 |
| Wild type | 301 (36.9%) | 416 (51.0%) | 161 (19.7%) | 557 (68.2%) | |||
| Stage | 0 | 234 (15.3%) | 256 (16.7%) | 0.023 | 113 (7.4%) | 376 (24.6%) | 0.025 |
| 1 | 141 (9.2%) | 229 (15.0%) | 64 (4.2%) | 307 (20.1%) | |||
| 2 | 263 (17.2%) | 308 (40.1%) | 143 (9.3%) | 428 (28.0%) | |||
| 3 | 42 (2.7%) | 48 (3.1%) | 19 (1.2%) | 71 (4.6%) | |||
| 4 | 2 (0.1%) | 8 (0.5%) | 0 (0.0%) | 10 (0.7%) | |||
| Tumour size | Less than 2cm | 242 (12.4) | 379 (19.4%) | <0.001 | 102 (5.2%) | 521 (26.6%) | <0.001 |
| 2cm or greater | 651 (33.2%) | 686 (35.0%) | 329 (16.8%) | 1007 (51.4%) | |||
| Tumour grade | 1 | 48 (2.5%) | 121 (6.4%) | <0.001 | 16 (0.8%) | 153 (8.1%) | <0.001 |
| 2 | 286 (15.1%) | 483 (25.6%) | 108 (5.7%) | 661 (35.0%) | |||
| 3 | 532 (28.2%) | 419 (22.2%) | 294 (15.6%) | 658 (34.8%) | |||
| ER status | Negative | 301 (15.6%) | 139 (7.2%) | <0.001 | 184 (9.5%) | 256 (13.2%) | <0.001 |
| Positive | 582 (30.1%) | 913 (47.2%) | 242 (12.5%) | 1254 (64.8%) | |||
The P values are resultant from Pearson χ2 test of association. ER is oestrogen receptor and PgR is progesterone receptor.